Pharmaceutical composition for treating hyperproliferative diseases

Abstract

The present invention relates to the field of biotechnology and medicine, in particular to a pharmaceutical composition having an antiproliferative activity and comprising an chimeric peptide and to a method of treating oncologic diseases, which includes introducing the chimerical peptide into a mammal requiring such treatment. The objective of the of invention is the development of a preparation that effectively penetrates the target cells and has a high cytostatic and cytotoxic activity.

1 - 13 . (canceled) 
     
     
         14 . A pharmaceutical composition comprising: (a) a pharmaceutically acceptable carrier, and (b) a chimeric peptide comprising a functional sequence of protein inhibitor of cyclin kinase p16INK4a (SEQ ID NO: 1) or p21/CIP/KIP (SEQ ID NO: 6) and a transport sequence, wherein the functional sequence and the transport sequence are linked by a group X, wherein X represents an amino acid sequence comprising from 1 to 50 amino acid residues, and wherein the chimeric peptide has the amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, or SEQ ID NO: 8. 
     
     
         15 . The pharmaceutical composition according to  claim 14 , wherein the chimeric peptide has the amino acid sequence of SEQ ID NO: 3. 
     
     
         16 . The pharmaceutical composition according to  claim 14 , wherein the chimeric peptide has the amino acid sequence of SEQ ID NO: 4. 
     
     
         17 . The pharmaceutical composition according to  claim 14 , wherein the chimeric peptide has the amino acid sequence of SEQ ID NO: 7. 
     
     
         18 . The pharmaceutical composition according to  claim 14 , wherein the chimeric peptide has the amino acid sequence of SEQ ID NO: 8. 
     
     
         19 . The pharmaceutical composition according to  claim 14 , wherein the chimeric peptide is in the amount of up to 400 mg/kg. 
     
     
         20 . A method of treating a hyperproliferative disease comprising administering to a mammal in need of such treatment the pharmaceutical composition according to  claim 14 . 
     
     
         21 . The method according to  claim 20 , wherein the hyperproliferative disease is cancer. 
     
     
         22 . The method according to  claim 21 , wherein the cancer is selected from the group consisting of colorectal cancer, renal cancer, lung cancer, breast cancer, bladder cancer, pancreatic cancer, uterine cancer, prostate cancer, gastric cancer and ovarian cancer. 
     
     
         23 . The method according to  claim 21 , wherein the mammal is a human. 
     
     
         24 . A method of treating a hyperproliferative disease comprising administering to a mammal in need of such treatment the pharmaceutical composition according to  claim 15 . 
     
     
         25 . The method according to  claim 24 , wherein the hyperproliferative disease is cancer. 
     
     
         26 . The method according to  claim 25 , wherein the cancer is selected from the group consisting of colorectal cancer, renal cancer, lung cancer, breast cancer, bladder cancer, pancreatic cancer, uterine cancer, prostate cancer, gastric cancer and ovarian cancer. 
     
     
         27 . The method according to  claim 24 , wherein the hyperproliferative disease is breast fibroadenoma. 
     
     
         28 . The method of  claim 24 , wherein the mammal is a human. 
     
     
         29 . The method of  claim 26 , wherein the mammal is a human. 
     
     
         30 . The method of  claim 24 , wherein the pharmaceutical composition is administered by local injection. 
     
     
         31 . A method of treating cancer comprising administering to a mammal in need of such treatment the pharmaceutical composition according to  claim 16 , wherein the cancer is selected from the group consisting of colorectal cancer, renal cancer, lung cancer, breast cancer, bladder cancer, pancreatic cancer, uterine cancer, prostate cancer, gastric cancer and ovarian cancer.